• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Argos Therapeutics Announces Participation in BIO 2007 International Convention Business Forum

Posted on: Monday, 30 April 2007, 12:00 CDT

Argos Therapeutics today announced that Jeffrey Abbey, M.B.A., J.D., Vice President of Business Development, will present at the BIO 2007 Business Forum on Monday, May 7th at 2:45 PM EST during the BIO 2007 International Convention at the Boston Convention & Exhibition Center.

Mr. Abbey will provide an update on the Company's dendritic cell-based immunotherapy programs developed with its "Arcelis" technology, and on its CD83 protein program for autoimmune disease and transplantation. Additional details on the convention can be found at www.bio2007.org.

About Argos Therapeutics, Inc.

Argos Therapeutics is developing breakthrough immunotherapies that target the unique features of a patient's disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company's "Arcelis" technology, trains the immune system to recognize and attack the disease. Argos' scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. www.argostherapeutics.com

Argos is a private biotechnology company headquartered in Research Triangle Park, NC. The Company has clinical trial programs in cancer and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the Pharmaceutical Division of Kirin Brewery Company, Limited.

Source: Business Wire

More News in this Category